Merits of the ‘good’ viruses: the potential of virus-based therapeutics

References

• Forterre P. Defining life: the virus viewpoint. Origins Life Evol Biosphere. 2010;40(2):151–160.
   PubMed Web of Science ®Google Scholar
• Raoult D, Forterre P. Redefining viruses: lessons from mimivirus. Nature Rev Microbiol. 2008;6(4):315–319.
   PubMed Web of Science ®Google Scholar
• Mietzsch M, Agbandje-McKenna A-M The good that viruses do. Annu Rev Virol. 2017;4(1):iii–v. %M 28961414 %U.
   PubMedGoogle Scholar
• Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat Rev Drug Discov. . 2015;14:515-516.
   Google Scholar
• Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013;161(4):355–364. %@ 1931–5244.
   PubMed Web of Science ®Google Scholar
• Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. Science. 2018;359(6372):eaan4672.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li S, Yu H, et al. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013;31(11):654–663..
   PubMed Web of Science ®Google Scholar
• Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659.
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Phage antibacterials make a comeback. Nat Biotechnol. 2001;19(8):734–735. %@ 1546–1696.
   PubMed Web of Science ®Google Scholar
• Salmond GPC, Fineran PC. A century of the phage: past, present and future. Nature Rev Microbiol. 2015;13(12):777–786.
   PubMed Web of Science ®Google Scholar
• Altamirano FLG, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066–18..
   PubMed Web of Science ®Google Scholar
• Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5(1):226–235.
   PubMed Web of Science ®Google Scholar
• Kortright KE, Chan BK, Koff JL, et al. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219–232.
   PubMed Web of Science ®Google Scholar
• Chan BK, Sistrom M, Wertz JE, et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016;6(1): 26717–26717. DOI:10.1038/srep26717.
   Google Scholar
• Ryan E, Alkawareek MY, Donnelly RF, et al. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol. 2012;65(2):395–398.
   PubMedGoogle Scholar
• Knezevic P, Curcin S, Aleksic V, et al. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Res Microbiol. 2013;164(1):55–60.
   PubMed Web of Science ®Google Scholar
• Roach DR, Leung CY, Henry M, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jang I, Yoon S, et al. Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother. 2017;61(6):6.
   Web of Science ®Google Scholar
• Kashani HH, Schmelcher M, Sabzalipoor H, et al. Recombinant endolysins as potential therapeutics against antibiotic-resistant staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev. 2017;31:1.
   Web of Science ®Google Scholar
• Solanki K, Grover N, Downs P, et al. Enzyme-based listericidal nanocomposites. Sci Rep. 2013;3(1): 1584–1584. DOI:10.1038/srep01584.
   Google Scholar
• Liu T, Galanis E, Kirn DH. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Rev Clin Prac Oncol. 2007;4(2):101–117.
   PubMedGoogle Scholar
• Kelly EJ, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–659.
   PubMed Web of Science ®Google Scholar
• Smith RR, Huebner RJ, Rowe WP, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9(6):1211–1218.
   PubMed Web of Science ®Google Scholar
• Milton GW, Brown MML. The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. ANZ J Surg. 1966;35(4):286–290.
   Google Scholar
• Pasquinucci G. Possible effect of measles on Leukaemia. Lancet. 1971;297(7690):136.
   Google Scholar
• Taqi AM, Abdurrahman MB, Yakubu AM, et al. Regression of Hodgkin’s disease after measles. Lancet. 1981;317(8229): 1112–1112. DOI:10.1016/S0140-6736(81)92286-8.
   Google Scholar
• Bluming A, Ziegler J. Regression of Burkitt’s lymphoma in association with measles infection. Lancet. 1971;298(7715):105–106.
   Google Scholar
• Hunter-Craig I, Newton KA, Westbury G, et al. Use of vaccinia virus in the treatment of metastatic malignant melanoma. BMJ. 1970;2(5708):512–515.
   PubMedGoogle Scholar
• Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34(6):1907–1928.
   PubMed Web of Science ®Google Scholar
• Roenigk HH, Deodhar S, St-Jacques R, et al. Immunotherapy of Malignant Melanoma With Vaccinia Virus. Arch Dermatol. 1974;109(5):668–673.
   PubMedGoogle Scholar
• Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Japan J Exper Med. 1987;57(1):79–81.
   PubMedGoogle Scholar
• Arakawajr S, Hamami G, Umezu K, et al. Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases. J Cancer Res Clin Oncol. 1987;113(1):95–98.
   PubMed Web of Science ®Google Scholar
• Everall JD, Wand J, Odoherty CJ, et al. Treatment of primary melanoma by intralesional vaccinia before excision. Lancet. 1975;306(7935):583–586.
   Google Scholar
• Shimizu Y, Hasumi K, Okudaira Y, et al. Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. CanDetec Preven. 1988;12(1–6):487.
   Google Scholar
• Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer. 1965;18(7):863–868.
   PubMed Web of Science ®Google Scholar
• Southam CM, Moore AE. Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus. Cancer. 1952;5(5):1025–1034.
   PubMed Web of Science ®Google Scholar
• Moore AE, Southam CM. West Nile, Ilheus, and Bunyamwera Virus Infections in Man 1,2,3. Am J Trop Med Hyg. 1951;s1-31(6):724–741.
   Web of Science ®Google Scholar
• Miest T, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nature Rev Microbiol. 2014;12(1):23–34.
   PubMed Web of Science ®Google Scholar
• Macedo N, Miller DM, Haq R, et al. Clinical landscape of oncolytic virus research in 2020. Journal for ImmunoTherapy of Cancer. 2020;8(2):e001486.
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Kirn DH, Williams A, et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells. Science. 1996;274(5286):373–376.
   PubMed Web of Science ®Google Scholar
• O’Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004;6(6):611–623.
   PubMed Web of Science ®Google Scholar
• Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018;18(2):171–176.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K. Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther. 2017;25(5):1107–1116.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS. Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016;22(13):3127–3131.
   PubMed Web of Science ®Google Scholar
• Raman SS, Hecht JR, Chan E. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019;11(8):705–723.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18(9):689–706.
   PubMed Web of Science ®Google Scholar
• Martin NT, Bell JC. Oncolytic Virus Combination Therapy: killing One Bird with Two Stones. Mol Ther. 2018;26(6):1414–1422.
   PubMed Web of Science ®Google Scholar
• Friedmann T, Roblin R. Gene Therapy for Human Genetic Disease? Science. 1972;1754025:949–955.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
   PubMed Web of Science ®Google Scholar
• Blaese RM, Culver KW, Miller AD, et al. T Lymphocyte-Directed Gene Therapy for ADA- SCID: initial Trial Results After 4 Years. Science. 1995;270(5235):475–480.
   PubMed Web of Science ®Google Scholar
• Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1(10):1017–1023.
   PubMed Web of Science ®Google Scholar
• Bordignon C, Notarangelo LD, Nobili N, et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients. Science. 1995;270(5235):470–475.
   PubMed Web of Science ®Google Scholar
• Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29(2):121–128.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, Saint-Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669–672.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science. 2003;302(5644):415–419.
   PubMed Web of Science ®Google Scholar
• Miller AD, Miller DG, Garcia JV, et al. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 1993;217:581–599.
   PubMed Web of Science ®Google Scholar
• David R, Doherty AT. Viral vectors: the road to reducing genotoxicity. Toxicol Sci. 2017;155(2):315–325.
   PubMed Web of Science ®Google Scholar
• Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263–267.
   PubMed Web of Science ®Google Scholar
• Kotterman MA, Chalberg TW, Schaffer DV. Viral Vectors for Gene Therapy: translational and Clinical Outlook. Annu Rev Biomed Eng. 2015;17(1):63–89.
   PubMedGoogle Scholar
• Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616–629.
   PubMed Web of Science ®Google Scholar
• Van Ginkel FW, McGhee JR, Liu C, et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Iimmunol. 1997;159(2):685–693.
   PubMed Web of Science ®Google Scholar
• Benihoud K, Esselin S, Descamps D, et al. Respective roles of TNF-α and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice. Gene Ther. 2007;14(6):533–544.
   PubMed Web of Science ®Google Scholar
• Oconnor T, Crystal RG. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet. 2006;7(4):261–276.
   PubMed Web of Science ®Google Scholar
• Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255–272.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol. 2011;23(3):377–382.
   PubMed Web of Science ®Google Scholar
• Liniger M, Zuniga A, Naim H. Use of viral vectors for the development of vaccines. Exp Rev Vaccines. 2007;6(2):255–266.
   PubMed Web of Science ®Google Scholar
• Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15(8):646–655.
   PubMed Web of Science ®Google Scholar
• Saxena M, Van TTH, Baird FJ. et al. Pre-existing immunity against vaccine vectors – friend or foe? Microbiology (Reading). 2013; 159(Pt_1): 1–11. PubMed PMID: 23175507; eng.
   PubMedGoogle Scholar
• Bayer M, Blumberg BS, Werner BG. Particles associated with Australia Antigen in the Sera of Patients with Leukaemia, Down’s Syndrome and Hepatitis. Nature. 1968;218(5146):1057–1059.
   PubMed Web of Science ®Google Scholar
• Millman I, Zavatone V, Gerstley BETTYJANES, et al. Australia Antigen detected in the Nuclei of Liver Cells of Patients with Viral Hepatitis by the Fluorescent Antibody Technique. Nature. 1969;222(5189):181–184.
   PubMed Web of Science ®Google Scholar
• Krugman S. The Newly Licensed Hepatitis B Vaccine: characteristics and Indications for Use. JAMA. 1982;247(14):2012–2015.
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307(5947):178–180.
   PubMed Web of Science ®Google Scholar
• Lua LHL, Connors NK, Sainsbury F, et al. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111(3):425–440.
   PubMed Web of Science ®Google Scholar
• Valeropacheco N, Pereztoledo M, Villasiskeever MA, et al. Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine. PLoS One. 2016;11:2.
   Web of Science ®Google Scholar
• Chang L-J, Dowd KA, Mendoza FH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014;384(9959):2046–2052.
   PubMed Web of Science ®Google Scholar
• Peters BS, Cheingsong-Popov R, Callow D, et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect. 1997;35(3):231–235.
   PubMed Web of Science ®Google Scholar
• Jones RM, Chichester JA, Mett V, et al. A Plant-Produced Pfs25 VLP Malaria Vaccine Candidate Induces Persistent Transmission Blocking Antibodies against Plasmodium falciparum in Immunized Mice. PLoS One. 2013;8(11):11.
   Web of Science ®Google Scholar
• Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33(8):848–858.
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot A, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25(1):63–72.
   PubMed Web of Science ®Google Scholar
• Beeh K, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131(3):866–874.
   PubMed Web of Science ®Google Scholar
• Fuenmayor J, Godia F, Cervera L. Production of virus-like particles for vaccines. New Biotechnology. 2017;39:174–180.
   PubMed Web of Science ®Google Scholar
• Koudelka KJ, Pitek AS, Manchester M, et al. Virus-based nanoparticles as versatile nanomachines. Annu Rev Virol. 2015;2(1):379–401.
   PubMedGoogle Scholar
• Rohovie MJ, Nagasawa M, Swartz JR. Virus-like particles: next-generation nanoparticles for targeted therapeutic delivery. Bioeng Transl Med. 2017 2017/03/01;2(1):43–57.
   PubMed Web of Science ®Google Scholar
• Hill BD, Zak A, Khera E, et al. Engineering virus-like particles for antigen and drug delivery. Curr Protein Pept Sci. 2017;19(1):112–127.
   Web of Science ®Google Scholar
• Tama F, Brooks CL. The mechanism and pathway of pH induced swelling in cowpea chlorotic mottle virus. J Mol Biol. 2002;318(3):733–747.
   PubMed Web of Science ®Google Scholar
• Almeida J, Edwards DC, Brand C, et al. Formation of virosomes from influenza subunits and liposomes. Lancet. 1975;306(7941):899–901.
   Google Scholar
• Uchida T, Kim J, Yamaizumi M, et al. Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. J Cell Biol. 1979;80(1):10–20.
   PubMed Web of Science ®Google Scholar
• Scheule RK. Novel preparation of functional Sindbis virosomes. Biochemistry. 1986;25(15):4223–4232.
   PubMed Web of Science ®Google Scholar
• Helenius A, Fries E, Kartenbeck J. Reconstitution of Semliki forest virus membrane. J Cell Biol. 1977;75(3):866–880.
   PubMed Web of Science ®Google Scholar
• Petri WA, Wagner RR. Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis. J Biol Chem. 1979;254(11):4313–4316.
   PubMed Web of Science ®Google Scholar
• Stegmann T, Morselt HWM, Booy FP, et al. Functional reconstitution of influenza virus envelopes. Embo J. 1987;6(9):2651–2659.
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69(1):531–569.
   PubMed Web of Science ®Google Scholar
• Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006;8(5):1287–1293.
   PubMed Web of Science ®Google Scholar
• Jain H, Kumavat V, Singh T, et al. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India. Hum Vaccin Immunother. 2014;10(7):2089–2097.
   PubMed Web of Science ®Google Scholar
• Lin RD, Steinmetz NF. Tobacco mosaic virus delivery of mitoxantrone for cancer therapy [10.1039/C8NR04142C]. Nanoscale. 2018;10 34:16307–16313.
   PubMed Web of Science ®Google Scholar
• Czapar AE, Zheng Y-R, Riddell IA, et al. Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy. ACS Nano. 2016;10(4):4119–4126.
   PubMed Web of Science ®Google Scholar
• Bruckman MA, Czapar AE, VanMeter A, et al. Tobacco mosaic virus-based protein nanoparticles and nanorods for chemotherapy delivery targeting breast cancer. J Control Release. 2016;231:103–113.
   PubMed Web of Science ®Google Scholar